- Home
- Applications
- switzerland
- targeted multiplexed protein
Show results for
Refine by
Targeted Multiplexed Protein Product Applications Available In In Switzerland
3 applications found
Several of the Navigo-created, ready-to-go Affilin molecules against solid tumor targets are currently developed as protein-drug conjugates (PDCs), by combining them to a half-life extending module and an engineered toxin-carrying moiety. Compared to notoriously difficult-to-produce and inhomogeneous Antibody-Drug Conjugates (ADCs), Affilin®-based PDCs have clear advantages. They are easily assembled from a specificity-conferring Affilin®, a half-life extending module and a toxin-carrying moiety. Each of ...
ByNavigo Proteins GmbH based in Halle, GERMANY
Solid tumor-specific Affilin molecules are currently being evaluated as CAR-T ligands. Specifically, they were confirmed to be functionally expressed on the effector cell surface, mediate target cell-binding and effective target cell-killing in a dose-dependent fashion. Importantly they were just as effective as commonly used antibody ...
ByNavigo Proteins GmbH based in Halle, GERMANY
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)